Key result
COVID-19 patients with elevated troponin I levels had a significantly higher risk of severe disease (RR 5.57), ICU admission (RR 6.20), and death (RR 5.64) compared to those with non-elevated levels.
Why the study?
It remained unclear whether cardiac injury-related biomarkers can independently predict mortality, severe disease development, or intensive care unit admission in patients with COVID-19.
Does elevated troponin I increase the risk of death, severe disease, or ICU admission in hospitalized patients with COVID-19?
Meta-Analysis (n=4,631)
Does elevated troponin I increase the risk of death, severe disease, or ICU admission in hospitalized patients with COVID-19?
Relative Risk: 5.57 (95% CI 3.04–10.22)
Absolute Event Rate: 64.5% vs 12%
p-value: p=<0.001
Elevated cardiac injury biomarkers, particularly troponin I, are strong independent predictors of severe disease, ICU admission, and mortality in hospitalized patients with COVID-19.
No takes yet. Share an insight, caveat, or question.
Elevated troponin may aid COVID-19 risk stratification; leaves open whether monitoring improves outcomes.
Li et al. (2020) conducted a meta-analysis in COVID-19 (n=4,631). Elevated Troponin I (TnI) or Troponin T (TnT) vs. Non-elevated TnI (or TnT) was evaluated on Severe disease (RR 5.57, 95% CI 3.04 to 10.22, p=<0.001). COVID-19 patients with elevated troponin I levels had a significantly higher risk of severe disease (RR 5.57), ICU admission (RR 6.20), and death (RR 5.64) compared to those with non-elevated levels.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: